Nectar Lifescience's Q3 FY 2025-26 Quarterly Results
- 24 Jan 2026
Result Summary
- Nectar Lifescience Ltd reported a 88.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 99.9%.
- Its expenses for the quarter were up by 416.0% QoQ and down 92.7% YoY.
- The net profit decreased 108.1% QoQ and increased 82.0% YoY.
- The earnings per share (EPS) of Nectar Lifescience Ltd stood at 0.64 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 0.66 | 5.74 | 455.56 | -88.5% | -99.9% |
Total Expenses | 32.20 | 6.24 | 443.00 | 416.0% | -92.7% |
Profit Before Tax | 56.60 | -0.51 | 12.55 | -11198.0% | 351.0% |
Tax | -11.02 | -0.18 | 4.71 | 6022.2% | -334.0% |
Profit After Tax | 14.27 | -176.01 | 7.84 | -108.1% | 82.0% |
Earnings Per Share | 0.64 | -7.84 | 0.35 | -108.2% | 82.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Nectar Lifescience Ltd is a company that operates primarily in the pharmaceutical sector. The firm is known for its involvement in the production and distribution of a range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and formulations. While specific recent developments for Nectar Lifescience Ltd are not detailed in the provided information, companies in this sector typically engage in research and development to enhance their product portfolio and meet regulatory standards. The pharmaceutical industry is characterized by stringent regulatory environments and a focus on innovation to address evolving healthcare needs.
Revenue
For the third quarter of the fiscal year 2026 (Q3FY26), Nectar Lifescience Ltd reported a total income of ₹0.66 crores, marking a significant decrease compared to the ₹5.74 crores recorded in the previous quarter (Q2FY26) and ₹455.56 crores in the same quarter of the previous year (Q3FY25). The quarter-over-quarter (QoQ) change in total income is a decline of 88.5%, while the year-over-year (YoY) change shows a decrease of 99.9%. These figures reflect substantial reductions in revenue compared to both recent quarters and the same period last year.
Profitability
The company's profit before tax for Q3FY26 was ₹56.60 crores, a notable improvement from a loss of ₹0.51 crores in Q2FY26 and a significant increase from ₹12.55 crores in Q3FY25. This illustrates an 11,198.0% QoQ increase and a 351.0% YoY increase. The tax expense for this quarter was recorded at -₹11.02 crores, compared to -₹0.18 crores in the previous quarter and ₹4.71 crores in the same quarter of the previous year, which indicates a substantial variation in tax treatment or benefits. As a result, the profit after tax was ₹14.27 crores, a recovery from a loss of ₹176.01 crores in Q2FY26 and higher than the ₹7.84 crores in Q3FY25, representing a QoQ change of -108.1% and a YoY increase of 82.0%.
Operating Metrics
Nectar Lifescience Ltd's total expenses for Q3FY26 were reported at ₹32.20 crores, which is a significant increase from ₹6.24 crores in Q2FY26, translating to a 416.0% increase QoQ. However, when compared to the same quarter in the previous year, where expenses were ₹443.00 crores, there is a decrease of 92.7% YoY. This considerable fluctuation in expenses could be indicative of changes in operational scale or cost management strategies. The earnings per share (EPS) for Q3FY26 was ₹0.64, up from a negative ₹7.84 in Q2FY26 and an increase from ₹0.35 in Q3FY25, showing a QoQ change of -108.2% and a YoY increase of 82.9%. These metrics provide insights into the company's earnings dynamics and operational efficiency over the reported periods.